US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Ophthalmology: market research reports

A portion of ophthalmology that resists change unlike some other specialties is the consumer reluctance to undertake a procedure that may have side effects associated with vision like refractive laser correction. Any side effects concerning eyes/vision is typically avoided as much as possible especially if there are other options.
Typically if the out-of pocket price for a life-enhancing procedure is within the budget of a consumer, the patient has a strong desire to get the procedure, and other factors are present that allow for it, the procedure is undertaken. In laser correction there has been skepticism which has diminished as more patients undertake the procedure with good results. While new ideas, breakthrough technologies, cost efficiencies, increased productivity,and new markets are the keys to growth and competitiveness, most people [work force; consumers; academics; politicians] are more confident in familiar environments. They will resist change unless their job, livelihood, or lifestyles are threatened.

This phenomenon is partly responsible for the trend toward closing solo and small group practices to join vision care networks. Though this experience exists more in general medical practices and some pecialties, ophthalmologists also face the threat of practitioners [osteopathic physicians, doctors of optometry] replacing eye MDs—an intrusion on their medical training, skills, and specialty. However increasing healthcare costs, and economic changes sometimes force shifts in the typical work pattern of healthcare providers. One example is a change that has happened in states across the U.S. allowing optometrists to diagnose and treat glaucoma.

RSS Feeds

Ophthalmology market research reports and industry analysis

< prev 1    3  4  5  6  7  8  9  10  
Open-Angle Glaucoma - Pipeline Review, H2 2014
7/15/2014 | published by: Global Markets Direct
... therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Global Ophthalmic Diagnostic Devices Market : 2014-2018
7/14/2014 | published by: TechNavio - Infiniti Research Ltd.
... Commenting on the report, an analyst from TechNavio’s team said: “The minimally invasive procedure, Laser Vision Correction, popularly called LASIK, has become extremely popular in the Healthcare industry. In the US alone, about 19 million ...  |  read more...
USD 2,500
Global Macular Edema Market : 2014-2018
7/7/2014 | published by: TechNavio - Infiniti Research Ltd.
... F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Alcon Inc., Alimera Sciences Inc., Allergan Inc., Ampio Pharmaceuticals Inc., iCo Therapeutics Inc.,Pfizer Inc., Santen Pharmaceutical Co. Ltd. Commenting on the report, an analyst from TechNavio’s ...  |  read more...
USD 2,500
Ophthalmics Partnering Terms & Agreements
7/1/2014 | published by: Current Partnering
... or development stage whereby the licensee obtains a right or an option right to license the licensors opthalmics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report ...  |  read more...
USD 1,995
Retinal Degeneration - Pipeline Review, H1 2014
6/30/2014 | published by: Global Markets Direct
... therapeutic development for Retinal Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014
6/30/2014 | published by: Global Markets Direct
... Exudative) Macular Degeneration’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of ...  |  read more...
USD 2,000
Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2014
6/25/2014 | published by: Global Markets Direct
... report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule ...  |  read more...
USD 2,000
Global Diabetic Retinopathy Market 2014-2018
6/13/2014 | published by: TechNavio - Infiniti Research Ltd.
... Ltd., Novartis AG , Pfizer Inc., Regeneron Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc. , Abbott Laboratories Ltd., Alcon Laboratories Inc., Alimera Sciences Inc., Allergan Inc., Ampio Pharmaceuticals Inc., Antisense Therapeutics Ltd., Bausch & Lomb Inc., ...  |  read more...
USD 2,500
Manufacturing Opticians (UK) - Industry Report
6/10/2014 | published by: Plimsoll Publishing Ltd.
... and ELLIVRON INVESTMENTS LTD. This report covers activities such as lenses, glasses, contact lenses, spectacles, optician and includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Manufacturing ...  |  read more...
USD 525
Global Age-Related Macular Degeneration (AMD) Market 2014-2018
6/6/2014 | published by: TechNavio - Infiniti Research Ltd.
... AG, F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Acucela Inc., Advanced Cell Technology Inc., Alexion Pharmaceuticals Inc., Alimera Sciences Inc., Allergen Inc., Allergo Opthalmics LLC, Avalanche Biotechnologies Inc., Gilead Sciences Inc., GlaxoSmithKline plc, ...  |  read more...
USD 2,500
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2014
5/30/2014 | published by: Global Markets Direct
... therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Juvenile Macular Degeneration (Stargardt Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of ...  |  read more...
USD 2,000
Global Uveitis Market 2014-2018
5/30/2014 | published by: TechNavio - Infiniti Research Ltd.
... Inc., Bausch & Lomb Inc., Artielle ImmunoTherapeutics Inc., Enzo Biochem Inc., Hanall Pharmaceutical Co. Ltd., Lux Biosciences Inc., OphthaliX Inc., Regeneron Pharmaceuticals Inc., TopiVertLtd., pSivida Corp., XOMA Corp., Santen Pharmaceutical Co. Commenting on the report, ...  |  read more...
USD 2,500
Viral Conjunctivitis - Pipeline Review, H1 2014
5/21/2014 | published by: Global Markets Direct
... therapeutic development for Viral Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Corneal Graft Rejection - Pipeline Review, H1 2014
5/15/2014 | published by: Global Markets Direct
... information on the therapeutic development for Corneal Graft Rejection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest ...  |  read more...
USD 2,000
Cataract - Pipeline Review, H1 2014
5/15/2014 | published by: Global Markets Direct
... Cataract, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It ...  |  read more...
USD 2,000
Uveal Melanoma - Pipeline Review, H1 2014
5/15/2014 | published by: Global Markets Direct
... therapeutic development for Uveal Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Update: Age-Related Macular Degeneration Pipeline Highlights – 2014
5/1/2014 | published by: Fore Pharma
... It covers emerging therapies for Age-Related Macular Degeneration in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating ...  |  read more...
USD 590
Market Highlights: France Age-related Macular Degeneration – 2014
5/1/2014 | published by: Fore Pharma
... forecast in France. The research includes France Age-related macular degeneration market size estimates for 2013, market share forecast for six years to 2019, Age-related macular degeneration drugs market share, Age-related macular degeneration drugs sales estimates, ...  |  read more...
USD 990
Market Highlights: Italy Cataract – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, cataract drugs market share, cataract drugs sales estimates, cataract drugs sales forecast, and cataract late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Market Highlights: UK Cataract – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, cataract drugs market share, cataract drugs sales estimates, cataract drugs sales forecast, and cataract late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Market Highlights: Italy Age-related Macular Degeneration – 2014
5/1/2014 | published by: Fore Pharma
... forecast in Italy. The research includes Italy Age-related macular degeneration market size estimates for 2013, market share forecast for six years to 2019, Age-related macular degeneration drugs market share, Age-related macular degeneration drugs sales estimates, ...  |  read more...
USD 990
Market Highlights: Japan Age-related Macular Degeneration – 2014
5/1/2014 | published by: Fore Pharma
... forecast in Japan. The research includes Japan Age-related macular degeneration market size estimates for 2013, market share forecast for six years to 2019, Age-related macular degeneration drugs market share, Age-related macular degeneration drugs sales estimates, ...  |  read more...
USD 990
Market Highlights: France Cataract – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, cataract drugs market share, cataract drugs sales estimates, cataract drugs sales forecast, and cataract late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Market Highlights: Europe Age-related Macular Degeneration – 2014
5/1/2014 | published by: Fore Pharma
... for Germany, France, Italy, Spain, and UK. The research includes Europe (Germany, France, Italy, Spain, and UK) Age-related macular degeneration market size estimates for 2013, market share forecast for six years to 2019, Age-related macular ...  |  read more...
USD 2,800
Market Highlights: Germany Cataract – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, cataract drugs market share, cataract drugs sales estimates, cataract drugs sales forecast, and cataract late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
< prev 1    3  4  5  6  7  8  9  10  
 
Our Clients